- What RevMed’s pancreatic cancer drug meant for one patientWhy did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."STAT · 1mo ago↗ source
- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialOtsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.STAT · 1mo ago↗ source
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseThe Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.